CHAPTER 1 INTRODUCTION
1.1 Objective and Scope of the Report
1.2 Key Deliverables of the Report
1.3 Unique Benefits of the Report
1.4 Key Audiences
1.5 Research Methodology
1.5.1 Secondary research
1.5.2 Primary research
1.5.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 GLOBAL FLOW CYTOMETRY MARKET OVERVIEW
3.1 Market Definition and Scope
3.1.1 Key applications of Flow cytometry
3.1.2 Application of Flow Cytometry in Gender Selection
3.1.3 Flow cytometry in Omics Technology
3.1.3.1 Applications of omics technology
3.1.3.1.1 Lung disease identification
3.1.3.1.2 Quantifying Abnormalities
3.1.3.1.3 Genetic Trait Diagnosis
3.1.3.1.4 Pharmacogenomics
3.1.4 Flow Cytometry in Immunophenotyping
3.1.4.1 Immunophenotyping in hematology applications
3.1.4.1.1 Erythrocyte analysis
3.1.4.1.2 Leukocyte Analysis
3.1.4.1.3 Platelet analysis
3.1.5 Flow cytometry in blood bank
3.1.6 Optimization of Flow Cytometry by Information Technology
3.1.7 Use Of Flow Cytometry In Resource-Poor Regions
3.2 Top factors impacting Flow cytometry Market
3.3 Top three winning strategies in the flow cytometry market
3.3.1 Product Launch
3.3.2 Agreement and Collaboration
3.3.3 Acquisition
3.4 Top investment pockets in flow cytometry market
3.4.1 Flow cytometry market- by clinical application
3.4.2 Flow cytometry market- by Research application
3.4.3 Flow cytometry market- by End users
3.5 Porter's Five Forces Analysis
3.5.1 Intense Competition DecliningSupplier's Power
3.5.2 Wide Range of Product Availability Enhances Buyer's Power
3.5.3 Strategies to Be in Place to Combat Competition
3.5.4 High Investment Restricting Low Investment New Comers
3.5.5 Pricing Issues Impacting Adoption Rates
3.6 Reimbursement Scenario
3.7 Regulatory Issues
3.7.1 Challenges- in FDA Clearance
3.7.2 Impact of ASR Rule
3.7.3 Validation Challenges- Cell-Based
3.7.4 Validation Requirements (CLIA, CAP)
3.7.5 LDT Guidelines on Cell-based Fluorescence
3.7.6 Change in Regulations
3.8 Case studies
3.8.1 Case study 1: Expansion of the number of antibody conjugates
3.8.2 Case study 2: Recognition of target antibodies conjugates, Anti-human CD3: FITC.
3.8.3 Case study 3: To prove precursor B acute lymphoblastic leukemia has unusual transformation
3.8.4 Case study 4: To develop software that can run faster than the current flow cytometer software
3.8.5 Case study 5: To validate the mechanism of a candidate biologic drug
3.9 Market Dynamics
3.9.1 Drivers
3.9.1.1 Technological advancements
3.9.1.2 Clinical and research fields
3.9.1.3 Increase in scope of Applications areas
3.9.1.4 Investment in R&D
3.9.1.5 Increase in number of patients
3.9.2 RESTRAINTS
3.9.2.1 Instrument costs
3.9.2.2 Need of awareness
3.9.2.3 Need of trained personnel
3.9.3 OPPORTUNITIES
3.9.3.1 In clinical approach
3.9.3.2 Research approach
CHAPTER 4 FLOW CYTOMETRY MARKET BY PRODUCT
4.1 Global flow cytometry market, by product type, 2012-2020, $million
4.1.1 Global flow cytometry Product market, by geography, 2012-2020, $million
4.2 Instruments
4.2.1 Global flow cytometry Product market ,by instruments, 2012-2020,$million
4.2.2 Global flow cytometry-instruments market, by geography, 2012-2020, $million
4.2.3 Key Market Drivers
4.2.3.1 Popularity of bench top flow cytometers
4.2.3.2 Technological trends
4.2.4 Platforms
4.2.4.1 Types of platforms
4.2.4.1.1 Single-Platform Approach
4.2.4.1.1.1 TYPES OF SINGLE PLATFORM
4.2.4.2 Global flow cytometry Product market, by platform, 2012-2020,$million
4.2.4.3 Global flow cytometry platform market, by geography, 2012-2020, $million
4.2.4.4 Sorters
4.2.4.4.1 Types of Sorters
4.2.4.5 Analysers
4.2.5 Replaceable Components
4.2.5.1 Drivers of Replaceable Components Market
4.2.5.2 Global flow cytometry replaceable components market, by types, 2012-2020, $million
4.2.5.3 Global flow cytometry replaceable components market, by geography, 2012-2020, $million
4.2.5.4 Filters
4.2.5.4.1 Types of filters
4.2.5.4.2 Global flow cytometry filters market, by geography, 2012-2020, $million
4.2.5.5 Lasers
4.2.5.5.1 Global flow cytometry lasers market, by geography, 2012-2020, $million
4.2.5.6 Detectors
4.2.5.6.1 Global flow cytometry detectors market, by geography, 2012-2020, $million
4.2.5.7 Others
4.2.5.7.1 Global flow cytometry other components market, by geography, 2012-2020, $million
4.2.6 Accessories
4.2.6.1 Global flow cytometry Accessories market, by geography, 2012-2020, $million
4.3 Reagents and Consumables
4.3.1 Drivers of Reagents and consumables market
4.3.2 Global flow cytometry reagents and consumables market, by type, 2012-2020, $million
4.3.3 Global flow cytometry reagents and consumables market, by geography, 2012-2020, $million
4.3.4 Antibodies
4.3.4.1 Global flow cytometry antibodies market, by geography, 2012-2020, $million
4.3.5 Dyes
4.3.5.1 Global flow cytometry dyes market, by geography, 2012-2020, $million
4.3.6 Beads
4.3.6.1 Global flow cytometry beads market, by geography, 2012-2020, $million
4.3.7 Others
4.3.7.1 Reagent kits
4.3.7.2 Beads
4.3.7.3 Solutions
4.3.7.4 Buffers
4.3.7.5 Global flow cytometry other reagents and consumables market, by geography, 2012-2020, $million
4.4 Software
4.4.1 Global flow cytometry market, by software, 2012-2020, $million
4.4.2 Global flow cytometry- software market, by geography, 2012-2020, $million
4.4.3 With-System Software
4.4.3.1 Global flow cytometry with system market, by geography, 2012-2020, $million
4.4.4 Third Party Software
4.4.4.1 Global flow cytometry- third party market, by geography, 2012-2020, $million
4.5 Services
4.5.1 Global flow cytometry services market, by geography, 2012-2020, $million
CHAPTER 5 FLOW CYTOMETRY MARKET BY TECHNOLOGY
5.1 Global flow cytometry market, by technology, 2012-2020, $million
5.2 Global flow cytometry- technology market, by geography, 2012-2020, $million
5.3 Bead-Based Flow cytometry
5.3.1 Drivers of Bead Based Flow Cytometry Market
5.3.1.1 Application in the field of genomics
5.3.1.2 Application in the field of proteomics
5.3.1.3 High competitive edge
5.3.2 Global flow cytometry bead based market, by geography, 2012-2020, $million
5.4 Cell Based Flow Cytometers
5.4.1 Global flow cytometry cell based market, by geography, 2012-2020, $million
CHAPTER 6 FLOW CYTOMETRY MARKET BY APPLICATION
6.1 Drivers of the Flow Cytometry Application Market
6.1.1 Research funds
6.1.2 Need for management in disease control
6.1.3 Increase in flow cytometry end users
6.2 Restraints of the flow cytometry application market
6.3 Global flow cytometry market, by applications, 2012-2020, $million
6.4 Global flow cytometry-application market , by geography, 2012-2020, $million
6.5 Research Applications
6.5.1 Global flow cytometry market, by research applications, 2012-2020, $million
6.5.2 Global flow cytometry-research application market, by geography, 2012-2020, $million
6.5.3 Cell Cycle Analysis and Cell Proliferation
6.5.3.1 Global flow cytometry Cell cycle analysis and Cell proliferation market, by geography, 2012-2020, $million
6.5.4 Apoptosis
6.5.4.1 Drivers of Apoptosis market
6.5.4.2 Global flow cytometry Apoptosis market, by geography, 2012-2020, $million
6.5.5 Cell Sorting
6.5.5.1 Global flow cytometry Cell sorting market, by geography, 2012-2020, $million
6.5.6 Transfection and Cell Viability
6.5.6.1 Global flow cytometry Transfection and Cell viability market, by geography, 2012-2020, $million
6.5.7 Others
6.5.7.1 Global flow cytometry other research application market, by geography, 2012-2020, $million
6.6 Clinical Applications
6.6.1 Global flow cytometry market, by clinical applications, 2012-2020, $million
6.6.2 Global flow cytometry clinical application market, by geography, 2012-2020, $million
6.6.3 Organ Transplantation
6.6.3.1 Drivers of Organ transplantation market
6.6.3.2 Global flow cytometry organ transplant market, by geography, 2012-2020, $million
6.6.4 Hematology Hematological Malignancies
6.6.4.1 Global flow cytometry Hematology hematological malignancies market, by geography, 2012-2020, $million
6.6.4.2 Myeloma
6.6.4.3 Lymphomas
6.6.4.4 Leukemia
6.6.5 Cancer and Solid Tumour
6.6.5.1 Drivers of Cancer and solid tumor market
6.6.5.2 Restraints of Cancer and solid tumor market
6.6.5.3 Global flow cytometry Cancer and solid tumor market, by geography, 2012-2020, $million
6.6.6 Immunodeficiency Disease-HIV Infection
6.6.6.1 Key facts about HIV
6.6.6.2 Drivers of HIV market
6.6.6.3 Restraints of HIV market
6.6.6.4 Global flow cytometry Immunodeficiency disease-HIV infectionmarket, by geography, 2012-2020, $million
6.6.7 Others
6.6.7.1 Global flow cytometry other clinical application market, by geography, 2012-2020, $million
CHAPTER 7 FLOW CYTOMETRY MARKET BY END USER
7.1 Global flow cytometry market, by end user, 2012-2020, $million
7.2 Global flow cytometry end user market, by geography, 2012-2020, $million
7.3 Commercial Organizations
7.3.1 Global flow cytometry commercial market, by geography, 2012-2020, $million
7.4 Medical Schools and Clinical Testing Labs
7.4.1 Global flow cytometry medical schools and clinical testing labs market, by geography, 2012-2020, $million
7.5 Hospitals
7.5.1 Global flow cytometry hospitals market, by geography, 2012-2020, $million
7.6 Academics
7.6.1 Global flow cytometry Academics market, by geography, 2012-2020, $million
7.7 Others
7.7.1 Global flow cytometry other end user market, by geography, 2012-2020, $million
CHAPTER 8 FLOW CYTOMETRY MARKET BY GEOGRAPHY
8.1 North America
8.1.1 Drivers of the North American Market
8.1.2 North American flow cytometry market, 2012-2020, $million
8.2 Europe
8.2.1 Drivers of the European market
8.2.2 European flow cytometry market, 2012-2020, $million
8.3 Asia Pacific and RoW
8.3.1 Asia and RoW flow cytometry market, 2012-2020, $million
CHAPTER 9 COMPANY PROFILES
9.1 Advanced Analytical Technologies, Inc (AATI)
9.1.1 Company Overview
9.1.2 Company Snapshot
9.1.3 Strategies and Development
9.1.4 Swot Analysis of Advanced Analytical Technologies
9.2 Merck Millipore
9.2.1 Company Overview
9.2.2 Company Snapshot
9.2.3 Business Performance
9.2.4 Strategies and Development
9.2.4.1 Primary strategies: Agreement
9.2.4.2 Other strategies
9.2.5 SwotAnalysis of Merck Millipore
9.3 Life Technologies Corporation
9.3.1 Company Overview
9.3.2 Company Snapshot
9.3.3 Business Performance
9.3.4 Strategies and Development
9.3.4.1 Primary Strategies: Agreement
9.3.4.2 Secondary Strategies: Launch and Acquisition
9.3.5 SwotAnalysis of Life Technologies Corporation.
9.4 Beckman Coulter, Inc.
9.4.1 Company overview
9.4.2 Company Snapshot
9.4.3 Strategies and Development
9.4.3.1 Primary strategies: product Launch
9.4.3.2 Secondary strategies: Agreement & acquisition
9.4.4 Swot Analysis OF Beckman Coulter, Inc.
9.5 Becton, Dickinson & Co.
9.5.1 Company Overview
9.5.2 Snapshot of Becton, Dickinson & CO.
9.5.3 Business Performance
9.5.4 Strategies and Development
9.5.4.1 Primary strategies: Launch
9.5.4.2 Other strategies
9.5.5 SWOT analysis of Becton, Dickinson & Co
9.6 Luminex Corporation
9.6.1 Company Overview
9.6.2 Snapshot
9.6.3 Business Performance
9.6.4 Strategies and Development
9.6.4.1 Primary strategies: Agreement
9.6.4.2 Other strategies
9.6.5 Swot Analysis of LUMINEX CORPORATION
9.7 AmnisCorporation
9.7.1 Company Overview
9.7.2 Snapshot
9.7.3 Strategies and Development
9.7.3.1 Primary strategies: Launch
9.7.3.2 Other strategies
9.7.4 SwotAnalysis of AmnisCorporation
9.8 Partec GmbH
9.8.1 Company Overview
9.8.2 Snapshot
9.8.3 Strategies and Development
9.8.4 SwotAnalysis of Partec GmbH
9.9 EBIOSCIENCE, Inc.
9.9.1 Company Overview
9.9.2 Snapshot
9.9.3 Business Performance
9.9.4 Strategies and Development
9.9.4.1 Primary strategies: launch
9.9.4.2 Other strategies
9.9.5 Swot Analysis of eBioscience, Inc.
9.10 MORPHOSYS AG
9.10.1 Company Overview
9.10.2 Snapshot
9.10.3 Business performance
9.10.4 Strategies and Development
9.10.4.1 Primary strategies: Agreement, Launch.
9.10.4.2 Other strategies
9.10.5 Swot Analysis of Morphosys AG